Aciphex Approved for Treatment of GERD in Adolescents The FDA has approved Eisai Corporations Aciphex (rabeprazole sodium) for the short-term (up to 8 weeks) treatment of gastroesophageal reflux disease (GERD) in adolescents 12 years of age and older.The approval is based on results...
US FDA approves Eisai's rabeprazole for GERD Eisai Corporation of North America, a wholly-owned subsidiary of Tokyo-based Eisai Co., Ltd., announced that the Food and Drug Administration (FDA) has approved Aciphex (rabeprazole sodium) 20 mg for the short-term (up to eight weeks)...
FDA approves Eisai's Aciphex for ages 12 and up _ FDA approves Eisai's Aciphex for ages 12 and up.
Eisai wins approval for GERD drug Included in the submission was a 12-week, multi-center, open-label, randomized, parallel-group study of 111 adolescent gastroesophageal reflux disease (GERD) patients.In this study, Aciphex was well tolerated in adolescent subjects,...
Eisai's Aciphex cleared for GERD by US FDA _ Eisai's Aciphex cleared for GERD by US FDA.
FDA approves Eisai€™s Aciphex for ages 12 and up _ FDA approves Eisai€™s Aciphex for ages 12 and up.
FDA Approves Rabeprazole for Short-Term Treatment of GERD in Adolescents -- The US Food and Drug Administration (FDA) has approved rabeprazole sodium (Aciphex) for the short-term (up to 8 weeks) treatment of gastro-oesophageal reflux disease (GERD) in adolescents aged 12 years and older.Rabeprazole is...
FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents WOODCLIFF LAKE, N.J., June 30 /PRNewswire/ -- Eisai Corporation of North America, a wholly-owned subsidiary of Tokyo-based Eisai Co., Ltd., announced today that the Food and Drug Administration (FDA) has approved ACIPHEX (rabeprazole...
FDA Approves Aciphex (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents /PRNewswire/ -- Eisai Corporation of North America, a wholly-owned subsidiary of Tokyo-based Eisai Co., Ltd., announced today that the Food and Drug Administration (FDA) has approved ACIPHEX (rabeprazole sodium) 20 mg for the short...
FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents WOODCLIFF LAKE, N.J., June 30 /PRNewswire/ -- Eisai Corporation of North America, a wholly-owned subsidiary of Tokyo-based Eisai Co., Ltd., announced today that the Food and Drug Administration (FDA) has approved ACIPHEX (rabeprazole...
FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents WOODCLIFF LAKE, N.J., June 30 /PRNewswire/ -- Eisai Corporation of North America, a wholly-owned subsidiary of Tokyo-based Eisai Co., Ltd., announced today that the Food and Drug Administration (FDA) has approved ACIPHEX (rabeprazole...
Is Suppressing Stomach Acid Safe? The saying goes that when all you have is a hammer, everything looks like a nail.Doctors may not be carpenters, but when it comes to heartburn, the hammer they wield most frequently is an acid-suppressing drug.
Drug companies have been...
June 16, 2008: Popular Prescriptions Can Cause Drug Dependence Doctors dont like the word addiction.It has overtones of moral weakness when applied to drugs like alcohol, nicotine, cocaine or heroin.
Physicians prefer the term dependence because it describes withdrawal symptoms rather than...
Headliner: Eisai Corporation's Robert Laverty After nearly a quarter of a century in leadership communications roles at Bristol-Myers Squibb and Novartis, Robert Laverty signed on in April as VP, US corporate communications at Eisai Corporation of North America.He's excited about the...
Methods for treating gastroesophageal reflux disease Title: United States Patent: 7,361,646 Inventors: Belanoff; Joseph K.(Woodside, CA) Assignee: Corcept Therapeutics, Inc.
(Menlo Park, CA) Appl.
No.: 10/702,950 Filed: November 5, 2003 This invention relates to the discovery that...
Use of Rx to OTC Switch as Product Management Tactic Enjoys Comeback /PRNewswire/ -- There are 14 prescription drugs that exceeded $20 billion in sales in 2006, that may have the potential to reach the over-the-counter market in four years.Prescription to OTC switches were frequent in 2006 and 2007 and a...
